Bedrocan Canada Launches True Compassionate Pricing – Reinforces Its Commitment To Affordable Medicine
TORONTO, Jan. 25, 2015 /CNW/ – Bedrocan Canada Inc. (“Bedrocan Canada”, “Company”), wholly‑owned subsidiary of Canopy Growth Corporation (“Canopy Growth”) (TSXV: CGC) has made medical cannabis more affordable for all Canadian patients with a new price structure called True Compassionate Pricing. Under True Compassionate Pricing, all six cannabis varieties produced by Bedrocan Canada will be priced at $5 per gram, making it the most affordable product line in Canada.
Many Canadians who medicate with cannabis are doing so because traditional pharmaceutical drugs have not been as effective at treating their symptoms or have undesirable side effects. The decision to consume medical cannabis is made more complex due to the cost of the medicine.
“With limited insurance coverage and taxation, the affordability of medical cannabis can be a significant barrier to chronically ill patients obtaining the benefits of a medical marijuana program,” said Jonathan Zaid, Member of Bedrocan Canada’s Patient Advisory Board and Executive Director of Canadians for Fair Access to Medical Marijuana. “With its True Compassionate Pricing, Bedrocan is helping patients by making their medicine more affordable.”
Bedrocan Canada currently produces six standardized whole-flower cannabis varieties that provide consistency and reliability to people managing a variety of medical conditions and symptoms. All strains are covered by the True Compassion Pricing promise and are guaranteed to be in stock.
“Bedrocan Canada’s production methods have been refined over two decades to maximize yield and eliminate genetic variance from harvest to harvest. Because of that we’re able to produce standardized varieties efficiently,” said Marc Wayne, President of Bedrocan Canada. “Now that our Toronto facility is operating at full capacity, we are in a position to offer lower prices to our clients, the vast majority of whom are paying out of pocket for their medication.”
Bedrocan Canada continues its active dialogue with the insurance industry to enhance insurance eligibility for medical cannabis and medical cannabis devices. The Company is also encouraging the patient community to write to the federal government in an effort to change the current applicability of sales tax to medical cannabis, a policy that is inconsistent with the treatment of other healthcare practitioner authorized medications. Patients can visit www.bedrocan.ca to download a letter to The Honourable Bill Morneau, Minister of Finance.
Working collaboratively, Bedrocan Canada strives to make medical cannabis more affordable for all Canadian patients.
About Bedrocan Canada
Bedrocan Canada is focused on medicinal cannabis production and research, including, the EQUAL Study, which is currently enrolling patients and evaluating how cannabis is affecting their quality of life of Canadian patients. Bedrocan’s standardized strains have been used by thousands of patients in seven countries around the world. www.bedrocan.ca
About Canopy Growth Corporation
Canopy Growth is Canada’s first publicly traded medical marijuana company and the first geographically diversified producer with multiple licenses under the Marihuana for Medical Purposes Regulations. Through its wholly owned subsidiaries, Tweed, Tweed Farms, and Bedrocan, the Company operates three state-of-the-art production facilities in Ontario and distributes marijuana across the country to Canadian patients managing a host of medical conditions. The Company is dedicated to educating healthcare practitioners, providing consistent access to high quality medication, conducting robust clinical research, and furthering the public’s understanding of how marijuana is used for medical purposes. www.canopygrowth.com
Original press release: http://www.newswire.ca/news-releases/bedrocan-canada-launches-true-compassionate-pricing—reinforces-its-commitment-to-affordable-medicine-566450421.html
